by 
On August 21, 2023, the FDA approved Abrysvo, a vaccine developed by Pfizer, for the prevention of respiratory syncytial virus (RSV) in infants through active immunization of pregnant individuals.
RSV is a common respiratory virus that can cause mild to severe illness in infants, young children, older adults, and people with certain chronic health conditions. It is the leading cause of hospitalization for infants under the age of 1 year.
Abrysvo is a single-dose vaccine that is given to pregnant women between 24 and 36 weeks of gestation. The vaccine works by stimulating the body to produce antibodies against RSV. These antibodies are then passed on to the fetus, providing protection against RSV infection.
In clinical trials, Abrysvo was shown to be effective in preventing RSV infection in infants. The vaccine was also shown to be safe, with no serious side effects reported.
The approval of Abrysvo is a major milestone in the fight against RSV. The vaccine is expected to help reduce the number of infants who are hospitalized with RSV infection.
Here are some additional details about Abrysvo:
- It is a live, attenuated vaccine, which means that it contains a weakened form of the RSV virus.
- It is given as a single intramuscular injection.
- It is approved for use in pregnant women between 24 and 36 weeks of gestation.
- The most common side effects of Abrysvo are mild and include pain, redness, and swelling at the injection site.
If you are pregnant and are interested in getting the RSV vaccine, talk to your doctor. They can help you decide if the vaccine is right for you.
